-
US Justice Dept releasing new batch of Epstein files
-
South Africa and Israel expel envoys in deepening feud
-
French eyewear maker in spotlight after presidential showing
-
Olympic dream 'not over', Vonn says after crash
-
Brazil's Lula discharged after cataract surgery
-
US Senate races to limit shutdown fallout as Trump-backed deal stalls
-
'He probably would've survived': Iran targeting hospitals in crackdown
-
Djokovic stuns Sinner to set up Australian Open final with Alcaraz
-
Mateta omitted from Palace squad to face Forest
-
Gold, silver prices tumble as investors soothed by Trump's Fed pick
-
Trump attorney general orders arrest of ex-CNN anchor covering protests
-
Djokovic 'pushed to the limit' in stunning late-night Sinner upset
-
Tunisia's famed blue-and-white village threatened after record rains
-
Top EU official voices 'shock' at Minneapolis violence
-
Kremlin says agreed to halt strikes on Kyiv until Sunday
-
Carrick calls for calm after flying start to Man Utd reign
-
Djokovic to meet Alcaraz in Melbourne final after five-set marathon
-
Italian officials to testify in trial over deadly migrant shipwreck
-
Iran says defence capabilities 'never' up for negotiation
-
UN appeals for more support for flood-hit Mozambicans
-
Lijnders urges Man City to pile pressure on Arsenal in title race
-
Fulham sign Man City winger Oscar Bobb
-
Strasbourg's Argentine striker Panichelli sets sights on PSG, World Cup
-
Jesus 'made love': Colombian president irks Christians with steamy claim
-
IAEA board meets over Ukraine nuclear safety concerns
-
Eurozone growth beats 2025 forecasts despite Trump woes
-
Israel to partially reopen Gaza's Rafah crossing on Sunday
-
Dutch PM-elect Jetten says not yet time to talk to Putin
-
Social media fuels surge in UK men seeking testosterone jabs
-
Forest face Fenerbahce, Celtic draw Stuttgart in Europa League play-offs
-
US speed queen Vonn crashes at Crans-Montana, one week before Olympics
-
Trump nominates former US Fed official as next central bank chief
-
Alcaraz defends controversial timeout after beaten Zverev fumes
-
New Dutch government pledges ongoing Ukraine support
-
Newcastle still coping with fallout from Isak exit, says Howe
-
Chad, France eye economic cooperation as they reset strained ties
-
Real Madrid to play Benfica, PSG face Monaco in Champions League play-offs
-
Everton winger Grealish set to miss rest of season in World Cup blow
-
Trump brands Minneapolis nurse killed by federal agents an 'agitator'
-
Arteta focuses on the positives despite Arsenal stumble
-
Fijian Drua sign France international back Vakatawa
-
Kevin Warsh, a former Fed 'hawk' now in tune with Trump
-
Zverev rails at Alcaraz timeout in 'one of the best battles ever'
-
Turkey leads Iran diplomatic push as Trump softens strike threat
-
Zelensky backs energy ceasefire, Russia bombs Ukraine despite Trump intervention
-
'Superman' Li Ka-shing, Hong Kong billionaire behind Panama ports deal
-
Skiing great Lindsey Vonn crashes at Crans-Montana, one week before Olympics
-
Slot warns Liverpool 'can't afford mistakes' in top-four scrap
-
Paris show by late Martin Parr views his photos through political lens
-
'Believing' Alcaraz outlasts Zverev in epic to reach maiden Melbourne final
| RBGPF | 1.65% | 83.78 | $ | |
| SCS | 0.12% | 16.14 | $ | |
| RYCEF | -2.69% | 16 | $ | |
| NGG | -0.33% | 84.77 | $ | |
| CMSC | -0.02% | 23.69 | $ | |
| AZN | 0.38% | 92.94 | $ | |
| GSK | 1.03% | 51.18 | $ | |
| BP | 0.09% | 38.075 | $ | |
| BTI | -0.47% | 59.93 | $ | |
| RIO | -3.08% | 92.29 | $ | |
| VOD | -0.55% | 14.63 | $ | |
| BCE | 0.1% | 25.51 | $ | |
| JRI | 0.23% | 12.985 | $ | |
| BCC | -1.31% | 79.132 | $ | |
| RELX | -1.25% | 35.72 | $ | |
| CMSD | 0.05% | 24.073 | $ |
Songji Biotech Launches 1,000-Dalton Marine Peptides Backed by Hualien Tzu Chi Hospital Research Collaboration
Songji Biotech Enterprise Co., Ltd. (SGBE) has announced the commercial launch of standardized 1,000-Dalton marine collagen peptides, scientifically validated for anti-aging efficacy through a collaborative study with Hualien Tzu Chi Hospital. Derived from sustainable milkfish scales using proprietary enzymatic hydrolysis technology, these low-molecular-weight peptides are engineered to overcome transdermal absorption barriers. SGBE supports the global market through its proprietary brand, Fishelton, and provides comprehensive OEM/ODM services from its ISO 22716 and GMP-certified facilities.
TAINAN, TAIWAN / ACCESS Newswire / January 27, 2026 / Songji Biotech Enterprise Co., Ltd. (SGBE) today announced the commercial launch of its standardized 1,000-Dalton marine collagen peptides. This release follows a collaborative study with Hualien Tzu Chi Hospital that validates the ingredient's potential in anti-aging applications. By utilizing enzymatic hydrolysis technology on milkfish scales, the company has achieved a molecular weight significantly below the 1,500-Dalton threshold, addressing a key technical barrier in transdermal absorption for the cosmetic industry.

Collaborative Research on Peptide Efficacy
To verify the biological activity of its ingredients, Songji Biotech partnered with the research team led by Vice Dean Huang Zhi-yang at Hualien Tzu Chi Hospital. The study utilized an H2O2-induced human skin fibroblast aging model to evaluate the specific collagen peptides produced by SGBE.
According to preliminary findings presented at the Healthcare+ Expo, the peptides showed no cytotoxicity in the tested models. The data indicated that SGBE's peptides contributed to increased cell survival rates and a reduction in inflammation markers mediated by NF-κB. Furthermore, the study suggested a positive correlation between the application of these peptides and collagen synthesis within the cellular model.
Overcoming the Molecular Weight Barrier
SGBE reports that its proprietary process consistently yields peptides with a molecular weight of approximately 1,000 Daltons (approx. 100 nanometers). This is a significant differentiation in the market, where standard animal-derived collagen typically ranges from 300,000 to 500,000 Daltons.
This low-molecular-weight profile is engineered to enhance solubility and stability against heat and acid. Technically, it allows the peptides to penetrate the stratum corneum more effectively, making them suitable for high-performance skincare formulations and functional oral supplements.

Sustainable Sourcing and Quality Assurance
The peptides are sourced exclusively from the scales of milkfish (Chanos chanos), a byproduct of Tainan's local aquaculture industry. This ensures a sustainable supply chain free from mammalian disease concerns.
"Our development focus is to bridge the gap between biotechnology and aquaculture," said Chiou Yang-haw, General Manager of Songji Biotech Enterprise Co., Ltd. "With the scientific data provided by our collaboration with Hualien Tzu Chi Hospital, we can now offer our global OEM partners a raw material that is not only sustainable but also scientifically verified for safety and efficacy."
Manufacturing Compliance
Songji Biotech confirms that its production facilities have maintained ISO 22716, GMP, and HACCP certifications. The company's ingredients are registered under the International Nomenclature of Cosmetic Ingredients (INCI), facilitating immediate adoption by international beauty and healthcare brands.

About Songji Biotech. Enterprise Co., Ltd.
Songji Biotech. Enterprise Co., Ltd. is a biotechnology company headquartered in Tainan, Taiwan, dedicated to the high-value utilization of marine resources. Through its proprietary extraction technologies, the company produces the Fishelton brand of skincare and health products and provides comprehensive OEM/ODM services for the global market.
For more information, please visit: https://fishelton.com.tw/?lang=en
Related Video Introduction:
Media Contact
Organization: Songji Biotech. Enterprise Co.,Ltd.
Contact Person Name: Chiou Yang-haw
Website: https://fishelton.com.tw/?lang=en
Email: [email protected]
Contact Number: +886800777978
Address: No. 14, Xinjia St., Xinying Dist.
City: Tainan
State: Taiwan
Country: Taiwan
SOURCE: Songji Biotech. Enterprise Co.,Ltd.
View the original press release on ACCESS Newswire
T.Wright--AT